Head-to-head trial dents Novo Nordisk's obesity hopes
Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.
Newsletters and Deep Dive digital magazine
Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.
For decades, the pharmaceutical industry has relied on accelerated development and manufacturing timelines to bring new therapies to patients quickly.
Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.
Daiichi Sankyo has named John Tsai as its new chief medical officer, replacing Ken Takeshita, who is stepping down after five years in the role.
MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.
Editor's Picks
Newsletters and Deep Dive
digital magazine